What is Elmiron?
Elmiron® (pentosan polysulfate sodium) has been on the market since the 90s, and it is the only drug approved to treat pain associated with Interstitial Cystitis (IC) — a condition that affects millions of Americans each year. IC, also known as “painful bladder syndrome,” is a chronic bladder condition with no known cure. IC is more prevalent in women, and many use Elmiron long term to treat the disease.
Starting in 2018, studies began to document irreversible vision problems associated with the long-term use of Elmiron. Maculopathy has been linked to long-term Elmiron usage, which is the primary cause of blindness. According to studies, this type of maculopathy seems to be unique to Elmiron users.
If caught in its early stages, the damage may stop after taking medication. But in late stages, the disease can lead to permanent vision loss. So far, researchers have reported on one patient whose eye damage continued for years even after stopping Elmiron.
The most common visual symptoms reported in studies were difficulty reading and difficulty adapting to dim lighting. Other symptoms include: blurred vision, halo vision, vision impairment, vision loss and more.
FDA drug safety label change
Long-term usage of Elmiron has been linked to serious vision issues, including blindness.
In June 2020, the FDA issued a Drug Safety-related Labeling Change for Elmiron, basically identifying that long-term usage of Elmiron resulted in pigmentary changes in the retina.
Extensive usage of Elmiron can lead to irreversible vision problems and even blindness. It is crucial to seek out testing & treatment if you have been taking Elmiron and experienced any problems with your vision.
Did you or someone you know experience vision issues after taking Elmiron? You may be entitled to compensation from the manufacturer. Please fill out the form or give us a call at(781) 350-0000 for a free case review.
Elmiron Lawsuit Sources:
FDA Drug Safety-related Labeling Changes – Elmiron (Pentosan Polysulfate Sodium)
Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium
Pentosan polysulfate therapy, a common treatment for interstitial cystitis, has been associated with a maculopathy.